Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients [Seeking Alpha]
Gain Therapeutics, Inc. (GANX)
Company Research
Source: Seeking Alpha
GT-02287's mechanism addresses GCase misfolding earlier in the disease process, potentially offering superior efficacy versus competitors. GANX's $66 million market cap is seen as deeply undervalued given positive trial data, large market potential, and higher-value biotech acquisitions. I reiterate a Strong Buy rating for GANX. Getty Images Thesis I am updating coverage of Gain Therapeutics ( GANX ) in light of the recent achievement of functional improvement in PD patients. I have covered Gain Therapeutics about a year ago. At the time, the company had finished its This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of GANX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking
Show less
Read more
Impact Snapshot
Event Time:
GANX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GANX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GANX alerts
High impacting Gain Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GANX
News
- Gain Therapeutics (NASDAQ:GANX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Gain Therapeutics' (GANX) Preclinical Momentum Drives Its Progress in Parkinson's Drug Development [Yahoo! Finance]Yahoo! Finance
- Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025GlobeNewswire
- Gain Therapeutics GAAP EPS of -$0.15 beats by $0.01 [Seeking Alpha]Seeking Alpha
GANX
Sec Filings
- 12/3/25 - Form S-8
- 11/28/25 - Form 8-K
- 11/28/25 - Form 424B5
- GANX's page on the SEC website